NCT02045940 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 20, 2014

Primary Completion Date

March 26, 2015

Study Completion Date

March 26, 2015

Conditions

Cachexia

Interventions

DRUG

GSK2881078

Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg

DRUG

Placebo

Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.

Trial Locations (2)

21225

GSK Investigational Site, Baltimore

66211

GSK Investigational Site, Overland Park